Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Stock Information for Capricor Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.